Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Abbvie Inc
Recent news which mentions Abbvie Inc
< Previous
1
2
Next >
Trump's drug price ultimatum sets pharma firms scrambling
August 01, 2025
Tags
Biotech and Pharmaceuticals
Amgen Inc
Roche Holding AG
From
CNBC.com News
Trump's pharmaceutical tariffs could affect some drugmakers more than others
July 29, 2025
Tags
Bristol/Myers Squibb Co
Vertex Pharmaceuticals Inc
Biotechnology
From
CNBC.com News
Trump threatens to put up to 200% tariff on pharmaceuticals 'very soon'
July 08, 2025
Tags
US: News
AbbVie Inc
Eli Lilly and Co
From
CNBC.com News
Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan
June 17, 2025
Tags
Breaking News: Business
Johnson & Johnson
Business
From
CNBC.com News
Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
June 17, 2025
Tags
LILLY DRN
Biotechnology
US: News
From
CNBC.com News
Jim Cramer suggests why it's hard to own traditional 'safety' stocks here
May 14, 2025
Tags
U/S/ Markets
Stock Picks
Investing
From
CNBC.com News
Novo Nordisk cuts 2025 guidance on weaker-than-expected Wegovy sales, posts first-quarter profit beat
May 07, 2025
Tags
Business News
Novo Nordisk A/S
Roche Holding AG
From
CNBC.com News
Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms
May 05, 2025
Tags
Breaking News: Business
Johnson & Johnson
Business
From
CNBC.com News
Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit
May 02, 2025
Tags
Roche Holding AG
Novo Nordisk A/S
LILLY DRN
From
CNBC.com News
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump’s pharma tariffs loom
April 30, 2025
Tags
Healthy Returns
Abbott Laboratories
LILLY DRN
From
CNBC.com News
Cramer's week ahead: Earnings from Tesla, Alphabet, Capital One and Boeing
April 17, 2025
Tags
Stock markets
American Airlines Group Inc
Tesla Inc
From
CNBC.com News
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
April 09, 2025
Tags
Johnson & Johnson
Business
Regeneron Pharmaceuticals Inc
From
CNBC.com News
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
April 01, 2025
Tags
Breaking News: Markets
Investment strategy
Health care industry
From
CNBC.com News
Ad spending on women's sports more than doubled last year
March 11, 2025
Tags
CNBC Sport
Sports TV
Business
From
CNBC.com News
Healthy Returns: AbbVie is the newest potential weight loss drug market player
March 04, 2025
Tags
Zealand Pharma A/S
Health & Science
Microsoft Corp
From
CNBC.com News
Cramer's Lighting Round: AbbVie is a buy
February 04, 2025
Tags
S&P 500
Hims & Hers Health Inc
Markets
From
CNBC.com News
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
January 17, 2025
Tags
Biotechnology
LILLY DRN
Bristol/Myers Squibb Co
From
CNBC.com News
Wednesday's big stock stories: What’s likely to move the market in the next trading session
October 29, 2024
Tags
Caterpillar Inc
New York Times Co
PRO: Playbooks
From
CNBC.com News
Cramer's Lightning Round: Sweetgreen is 'terrific'
October 16, 2024
Tags
GXO Logistics Inc
Market Outlook
Abbvie Inc
From
CNBC.com News
Friday's big stock stories: What’s likely to move the market in the next trading session
August 22, 2024
Tags
Boston Scientific Corp
Meta Platforms Inc
Investing
From
CNBC.com News
Biden administration to release prices for first 10 drugs subject to landmark Medicare negotiations
August 15, 2024
Tags
Breaking News: Business
AstraZeneca PLC
Johnson & Johnson
From
CNBC.com News
Healthy Returns: What drugmakers are saying about final negotiated prices with Medicare
August 06, 2024
Tags
Biotech and Pharmaceuticals
Politics
Abbvie Inc
From
CNBC.com News
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
May 01, 2024
Tags
Alvotech SA
CVS Health Corp
Health & Science
From
CNBC.com News
AbbVie taps longtime executive Robert Michael as new CEO, succeeding Richard Gonzalez
February 20, 2024
Tags
Health & Science
Pharmaceuticals
Companies
From
CNBC.com News
After 8 months stuck in orbit, Varda's drug spacecraft gets FAA approval to return
February 14, 2024
Tags
US: News
Aerospace & Defense
Breaking News: Business
From
CNBC.com News
Cramer's Lightning Round: AbbVie is 'a very good company'
February 08, 2024
Tags
MercadoLibre Inc
Stock markets
Investment strategy
From
CNBC.com News
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
January 28, 2024
Tags
Bristol/Myers Squibb Co
Moderna Inc
US: News
From
CNBC.com News
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
January 08, 2024
Tags
Abbvie Inc
Biotech and Pharmaceuticals
Breaking news
From
CNBC.com News
Cramer names biopharma companies to watch as industry mergers start to pile up
January 05, 2024
Tags
Investment strategy
Seagen Inc
ImmunoGen Inc
From
CNBC.com News
Pfizer shares fall as 2024 revenue and profit forecast disappoints
December 13, 2023
Tags
Breaking news
Health care industry
Business News
From
CNBC.com News
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.